Serum and urinary biomarkers for detection and active surveillance of prostate cancer

Maria F. Becerra, Abhishek Bhat, Ali Mouzannar, Venkatasai S. Atluri, Sanoj Punnen

Research output: Contribution to journalReview article

Abstract

Purpose of reviewTo provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them.Recent findingsThe limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today.SummaryDespite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.

Original languageEnglish (US)
Pages (from-to)593-597
Number of pages5
JournalCurrent opinion in urology
Volume29
Issue number6
DOIs
StatePublished - Nov 1 2019

    Fingerprint

Keywords

  • active surveillance
  • clinically significant cancer
  • prostate cancer
  • serum biomarkers
  • urine biomarkers

ASJC Scopus subject areas

  • Urology

Cite this